First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.
Lecia V. Sequist
Consultant or Advisory Role - Clovis (U)
Research Funding - Clovis
Jean-Charles Soria
Research Funding - Clovis
Shirish M. Gadgeel
Research Funding - Clovis
Heather A. Wakelee
Research Funding - Clovis
D. Ross Camidge
Honoraria - Clovis
Research Funding - Clovis
Andrea Varga
Research Funding - Clovis
Panos Fidias
Research Funding - Clovis
Antoinette J. Wozniak
Research Funding - Clovis
Joel W. Neal
Research Funding - Clovis
Robert Charles Doebele
Research Funding - Clovis
Edward B. Garon
Research Funding - Clovis
Sarah S. Jaw-Tsai
Employment or Leadership Position - Clovis
Consultant or Advisory Role - Clovis
Stock Ownership - Clovis
Jennifer C. Stern
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Jonathan Wade Goldman
Honoraria - Clovis
Research Funding - Clovis